HOUSTON--(BUSINESS WIRE)--Houston-based Aggredyne, Inc., a biomedical diagnostics company widely recognized as a leader in the field of platelet function testing, has appointed Dr. Jeffrey Dahlen as Vice President of Clinical and Scientific Affairs and General Manager of Aggedyne’s Asia-Pacific operations.
Dr. Dahlen is well known throughout the industry because of his many accomplishments achieved during 15 years of experience and service in the development and production of in-vitro diagnostics. He is especially noted for his ability to administer large clinical trials and for advancing the field of platelet function testing.
Before joining Aggredyne, Dr. Dahlen was Vice President of Medical and Scientific Affairs for Accriva Diagnostics, formed by the acquisition of Accumetrics, Inc. by International Technidyne, Inc. (ITC) in August 2013. Accumetrics had been a leader in platelet function testing.
Dr. Dahlen said he chose to join the Aggredyne team “because it is poised to become the leader in platelet function testing, a field to which I have dedicated most of my career. This field is important because many patients treated with antiplatelet medications have a poor response to their therapy and are left unprotected. Aggredyne’s AggreGuide platform is an excellent model for in-vitro platelet aggregation, and it is versatile, with potential to expand beyond platelet function testing to a full array of coagulation tests.”
“Since recently earning FDA clearance on our test platform and first assay (AggreGuideTM A-100 AA Assay for aspirin effect), we are ready to advance Aggredyne to the next level. Bringing Dr. Dahlen’s knowledge, experience, and stature to our team is a significant and validating milestone in growing Aggredyne,” said Dr. Edward Teitel, Aggredyne Chairman and CEO.
Dr. Dahlen earned a Bachelor of Science degree from the University of Illinois and a Doctor of Philosophy in Biomedical Sciences, Biochemistry & Molecular Biology from the University of New Mexico.
Aggredyne, Inc. (www.aggredyne.com), is a biomedical company founded in 2011 by Edward R. Teitel, MD, JD, and Robert C. Hux, CPA, to commercialize the AggreGuideTM platelet function analyzer. The AggreGuide system is an in-vitro diagnostic test that measures how sticky a patient’s platelets are and how well the patient is responding to antiplatelet medications, such as aspirin or Plavix® (clopidogrel).
SAFE HARBOR STATEMENT
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements in this release regarding Aggredyne’s business that are not historical facts are “forward-looking statements,” which involve risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements.